Revenues for the quarter were $11.4 million, up 19 percent over last year's revenues of $9.6 million during the same period.
Research and development costs more than doubled, to $11 million from $5.4 million during the year-ago period. This increase was due to costs of clinical trials, according to the company.
Decode's net loss for the quarter remained flat at $13.3 million, or $.25 per share.
As of June 30, Decode had $185.3 million in cash and short-term investments, including restricted cash.